Investigated for use/treatment in amyotrophic lateral sclerosis (ALS) and alzheimer's disease.
- Mechanism
- Curator reviewed
Xaliproden is an orally-active, synthetic, non-peptidic 5-hydroxytryptamine (5-HT) 1A receptor agonist with neurotrophic and neuroprotective activities. Although its mechanism of action is not fully understood, xaliproden appears to either mimic the effects of neurotrophins or stimulate their synthesis, thereby stimulating neuronal cell differentiation and proliferation and inhibiting neuronal cell death. The neuroprotective effect of this agent involves the activation of MAP kinase pathways via stimulation of the 5-HT1A receptor.
- Primary indication
- Investigated for use/treatment in amyotrophic lateral sclerosis (ALS) and alzheimer's disease.Curator reviewed
- Formula / weight
- C24H22F3N · 381.442 g/mol (avg)
- Code names
- SR-57746 · SR 57746A
Resolves to
WJJYZXPHLSLMGE-UHFFFAOYSA-NSMILESFC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC3=CC=CC=C3C=C2)CC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Xaliproden, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account